Skip to content
lifestyle.thedishh.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Halozyme, Inc.
Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance
January 28, 2026
Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update
January 23, 2026
Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE®
January 8, 2026
Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity
January 5, 2026
U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer
December 20, 2025